← Back to Search

Intramuscular (IM) Poly ICLC for Prostate Cancer

Phase 1
Waitlist Available
Led By Ashutosh K. Tewari, MD
Research Sponsored by Ashutosh Kumar Tewari
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 12
Awards & highlights

Summary

This trial tests a new treatment that injects a substance into specific areas of the body to help the immune system fight high-risk cancer. It aims to find the safest dose and understand any side effects. The treatment works by boosting the immune system to attack cancer cells, training it to recognize these cells better, and keeping it active against future cancer spread.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Dose-Limiting Toxicity level
Secondary study objectives
Number of adverse events
Time to PSA progression

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment3 Interventions
Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
Group II: Cohort 3Experimental Treatment3 Interventions
Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
Group III: Cohort 2Experimental Treatment3 Interventions
Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
Group IV: Cohort 1Experimental Treatment3 Interventions
Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intratumoral (IT) Poly ICLC 0.5 mg
2017
Completed Phase 1
~20
Carboxymethylcellulose
FDA approved
Carboxymethylcellulose
FDA approved
Radical Prostatectomy
2005
Completed Phase 2
~4550

Find a Location

Who is running the clinical trial?

Ashutosh Kumar TewariLead Sponsor
2 Previous Clinical Trials
141 Total Patients Enrolled
1 Trials studying Prostate Cancer
27 Patients Enrolled for Prostate Cancer
Oncovir, Inc.Industry Sponsor
23 Previous Clinical Trials
646 Total Patients Enrolled
1 Trials studying Prostate Cancer
14 Patients Enrolled for Prostate Cancer
Ashutosh K. Tewari, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top